tremelimumab and durvalumab
[13]. [41]. Search terms were “tremelimumab”, “durvalumab,” and “trial or clinical trial or clinical study.” Reference lists of relevant published studies and review articles were manually searched for more eligible trials. SBRT to 2-5 metastases will be administered between cycles 2 and 3 of immunotherapy. [14]. [28–32] All the selected studies were included in the systematic review, and 3 of 5 were included in the meta-analysis.[28–30]. Nat Immunol 2013;14:1212–8. A random-effect model was used due to the synthesis of different cancer types. Inhibitors of programmed cell death-1 (PD-1) and its ligand (PD-L1) have shown improved survival compared to chemotherapy on the treatment of advanced solid tumors. [9]. This website uses cookies. Pooled results showed that combining durvalumab and tremelimumab did not significantly improve the ORR compared with durvalumab (OR 1.12, 95% CI 0.43–2.90, P = .81) or tremelimumab (OR 2.40, 95% CI 0.47–12.32, P = .29) (Fig. For pooled analyses of the ORR and DCR in randomized studies, the Cochrane Risk of Bias Tool was applied to evaluate the risk of bias. Durvalumab and Tremelimumab every 3 weeks in concurrence with chemotherapy, followed by durvalumab monotherapy every 4 weeks. Annu Rev Immunol 2008;26:677–704. Open Med 2009;3:e123–30. Nat Med 2018;24:986–93. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. J Clin Oncol 2011;29:4828–36. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. T-cell homing specificity and plasticity: new concepts and future challenges. The trial was suspended in late 2019 after criteria were not met, but researchers estimate completion in 2024. Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in
Durvalumab and tremelimumab are drugs both given through intravenous infusion that act through different pathways to stimulate the body’s immune system to fight cancerous cells. Therefore, ethical approval was not necessary. All enrolled studies are phase I or II clinical trials, whereas data from randomized controlled phase III studies are lacking. Oncologist 2019;24:1453–61. [54–56] However, T cell exhaustion could drive a decline in the ability of T cells to kill tumor cells. [49]. [31]. We found that treatment with tremelimumab plus durvalumab in the first-line and second-line setting was clinically active and safe in patients with unresectable mesothelioma. Adv Immunol 2006;90:51–81. Durvalumab has no prior approvals to treat HCC in any country. Schneider H, Downey J, Smith A, et al. [12] Remarkable clinical activity and manageable safety of durvalumab were reported in various solid tumors, including melanoma, lung cancer, head and neck cancer, breast cancer, and urothelial carcinoma. Massard C, Gordon MS, Sharma S, et al. The first author, year of publication, register number, study design, county, cancer type, number of patients, mean age, lines of prior therapy, dosing schedule, objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events data reporting in the articles and supplementary materials were collected from each eligible study. Most patients had received 1 line of prior systemic therapy. Methods: This is a single arm exploratory investigator-initiated trial planned to include 57 pts to receive mFOLFOX6 (6cycles) in combination with durvalumab (150mg/q2W) and tremelimumab (75mg/q4W). JAMA Oncol 2017;3:e172411. durvalumab; immunotherapy; meta-analysis; solid tumor; tremelimumab. The OS survival rates at 18 months were 32.0% in the durvalumab + EP arm, 30.7% in the tremelimumab + durvalumab + EP group, and 24.8% in the EP cohort; at 24 months, those rates were 22.2%, 23.4%, and 14.4%, respectively. [34]. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. In addition, PD-L1 is expressed in tumor-infiltrating immune cells. Segal NH, Ou SI, Balmanoukian A, et al. modify the keyword list to augment your search. However, higher effects were not observed in the combination therapy group. Treatment-related deaths were 12 in the tremelimumab + durvalumab + EP arm, 6 in the durvalumab + EP arm, and 2 in the EP arm. We excluded 168 records because they were reviews/comments/letters/ news (n = 55), conference abstracts (n = 109), case reports (n = 3), or unregistered studies (n = 1). Accordingly, the meta-analyses of ORR and DCR were at moderate risk of reporting bias (Fig. (4) studies were prospective and registered clinical trials. Durvalumab with or without, [30]. [33–35] Nowadays, immune checkpoint inhibitors have revolutionized the treatment of patients with solid tumors. Grande E, Guerrero F, Puente J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. In this study, the combination therapeutic regimen showed no significant increase in treatment-related adverse events. 5). Cancer Biol Ther 2019;20:6–7. Four hundred eighty-seven potential records were included for the initial assessment. Wolters Kluwer Health
Hallmarks of cancer: the next generation. [38]. This category only includes cookies that ensures basic functionalities and security features of the website. RevMan version 5.3 software (Cochrane Collaboration's Information Management System) was used to meta-analyzed the above-mentioned data. Findings from CASPIAN reported previously for the last of the 2 treatment arms showed that, after a median follow-up of 14.2 months, the addition of the durvalumab improved the median OS to 13.0 months versus 10.3 months with EP alone (HR 0.73; 95% CI 0.59-0.91; P=0.0047) [2]. However, there were no significant differences between dual immunotherapy and mono-immunotherapy in pancreatic ductal adenocarcinoma and gastric and gastroesophageal junction adenocarcinoma. | Privacy Policy. [52]. However, a lower risk of any grade treatment-related adverse events was seen in HNSCC (RR 0.92). The combined effect of the two products may produce a stronger The combination of tremelimumab and durvalumab appeared active, with a good safety profile in patients with mesothelioma, warranting further exploration. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. The magnitude of the benefit is very similar and very consistent across all the prespecified subgroups of patients analysed, including those treated with cisplatin or those patients with liver or brain metastases,” said Prof. Paz-Ares. Some error has occurred while processing your request. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Cancer immunoediting: from immunosurveillance to tumor escape. [4]. [3,4] PD-1 inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors are immune checkpoint antibodies with distinct but complementary mechanisms of action. Ann Oncol 2019;30:1279–88. Please try again soon. Cohen EEW, Soulieres D, Le Tourneau C, et al. Medicine. [16]. Tumor-infiltrating lymphocytes are associated with the response to immunotherapy. Keyword Highlighting
Data from randomized studies (ORR and DCR) was assessed by odds ratio (OR) and 95% confidence interval (CI). A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to … [30] Nevertheless, durvalumab plus tremelimumab showed similar efficacy to durvalumab monotherapy in recurrent or metastatic head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Durvalumab plus tremelimumab showed similar risks of any grade treatment-related adverse events with durvalumab monotherapy (RR 1.01, 95% CI 0.69–1.49, P = .95) and tremelimumab monotherapy (RR 1.02, 95% CI 0.79–1.32, P = .87) (Fig. You also have the option to opt-out of these cookies. Phase 2 study of, [22]. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Proc Natl Acad Sci U S A 2018;115:E4041–50. Giving durvalumab and tremelimumab may help prevent cancer from returning (called cancer recurrence) when tumor DNA is detected in the blood. Consequently, in March 2020, the FDA approved durvalumab in combination with EP as first-line therapy for ES-SCLC. These cookies do not store any personal information. The blockage of CTLA-4 and PD-1 exerts critical anti-tumor effects. Figure 1 displays the selection process. Cancer Immunol Res 2015;3:1052–62. Three studies comprised durvalumab monotherapy and 2 studies contained tremelimumab monotherapy. All patients will receive one of the following standard of care chemotherapy regimens every 3 weeks for 6 cycles: cisplatin+ gemcitabine to maintaining your privacy and will not share your personal information without
[21]. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. [7]. All registration fields are required. Several limitations exist in this analysis. [47]. After 6 cycles of chemotherapy, patients are treated with durvalumab untils progression. It is mandatory to procure user consent prior to running these cookies on your website. Siu LL, Even C, Mesia R, et al. Postow MA, Chesney J, Pavlick AC, et al. [51]. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. A random-effects model was applied in the analyses owing to the small size of enrolled studies. Writing – original draft: Bi-Cheng Wang, Ji-Quan Fan, Quentin Liu. J Clin Oncol 2005;23:8968–77. Patients and Methods: Second-line patients were randomized 2:2:1 to receive durvalumab plus tremelimumab (arm A), or durvalumab (arm B) or tremelimumab … Wang, Bi-Cheng MDa,∗; Li, Peng-Cheng MDa; Fan, Ji-Quan MSa; Lin, Guo-He MDb; Liu, Quentin MDc, aCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, bDepartment of Oncology, the Second Affiliated Hospital of Anhui Medical University, Hefei. The rates of grade 3/4 and serious AEs were, respectively, 70.3% and 45.5% in the tremelimumab + durvalumab + EP arm, 62.3% and 32.1% in the durvalumab + EP arm, and 62.8% and 36.5% in the EP group. In a randomized, double-blind, phase II study, the response rates of melanoma patients were significantly higher in nivolumab plus ipilimumab group (61%) than in ipilimumab group (11%) (P < .001). Nizam A, Aragon-Ching JB. Okazaki T, Chikuma S, Iwai Y, et al. AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. A phase 3b safety study of fixed-dose durvalumab +, [26]. [27]. One study was phase 1b clinical trial, 1 was phase 1b/2 clinical trial, and three were phase 2 clinical trials. [5]. Cell 2011;144:646–74. [53]. Mechanisms of immune evasion by tumors. 800-638-3030 (within USA), 301-223-2300 (international)
Medicine (Baltimore) 2019;98:e18054. [36,37] Both CTLA-4 and PD-1 are able to regulate the activation of T-cell, however, the mechanisms of action were distinct. Cancer Med 2019;8:5969–78. N Engl J Med 2018;379:2342–50. Safety and efficacy of durvalumab with or without, [29]. During recent years, dual immune checkpoint inhibition has been a new treatment strategy for advanced patients. Durvalumab plus tremelimumab was superior to tremelimumab monotherapy in improving disease control rate in head and neck squamous cell carcinoma. Senan S, Shire N, Mak G, et al. Miska J, Abdulreda MH, Devarajan P, et al. J Exp Med 2000;192:1027–34. Paz-Ares LG, et al. [40–42] In the peripheral tissues, PD-1 limits the activation of T-cell through suppressing the induction of cytokines and the expression of anti-apoptotic proteins. Hellmann MD, Rizvi NA, Goldman JW, et al. Both durvalumab and tremelimumab have been tested for mesothelioma alone, but not in combination. [43]. To evaluate the efficacy and safety of durvalumab in combination with tremelimumab compared with either drug alone. (6) efficacy and safety data were available. ‘green + ’: low risk, ‘red -’: high risk, ‘yellow?’: unclear risk of bias. Eligibility criteria included PD-L1-low/negative disease that had progressed after 1 platinum-containing regimen in the R/M setting. [email protected]. One hundred sixty-four duplicates were excluded. Basic characteristics of the selected prospective and registered clinical trials. (A) Each risk of bias item presented as percentages across all included randomized clinical studies; (B) Each risk of bias item for each included randomized clinical study. Venkatraman D, Anderson A, Digumarthy S, et al. Paz-Ares LG, et al. The addition of tremelimumab to durvalumab (Imfinzi) and the standard of care (SOC), platinum-based chemotherapy, did not demonstrate a statistically significant improvement in overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC), missing the co-primary end point of the phase III CASPIAN trial (NCT03043872), according to high-level results from the final analysis … 1 Introduction. Additionally, pooled analyses illustrated that no significant differences in treatment-related adverse events were displayed between the 2 groups. Patients will receive durvalumab (1500 mg IV every 4 weeks (Q4W)) and tremelimumab (75 mg IV Q4W for a total of 4 doses) until progression, unacceptable toxicity or patient withdrawal. Secondary analyses suggested that tremelimumab resulted in increased antitumour activity, albeit with greater toxicity, when given in combination with durvalumab. Patients received durvalumab (1500 mg every 4 weeks) plus tremelimumab (75 mg every 4 weeks) combination therapy for 4 cycles followed by durvalumab therapy (1500 mg every 4 weeks) or durvalumab monotherapy (1500 mg every 4 weeks) for up to 12 months or until the onset of progressive disease or unacceptable toxic effects. The item(s) has been successfully added to ", This article has been saved into your User Account, in the Favorites area, under the new folder. The analysis of ORR and DCR comprised 3 types of cancers that might not fully represent the efficacy of combination therapy in solid tumors. [19]. The median OS for this combination was 10.4 months versus 10.5 months for EP alone (HR 0.82; 95% CI 0.68-1.00; P=0.0451). In addition, no statistically significant differences were observed in DCR when comparing combination therapy against monotherapy (durvalumab and tremelimumab versus durvalumab: OR 1.09, 95% CI 0.39–3.02, P = .87; durvalumab and tremelimumab versus tremelimumab: OR 2.76, 95% CI 0.28–27.24, P = .38) (Fig. Science 2006;313:1972–5. [55]. [48]. Reck M, Borghaei H, O’Byrne KJ. [38] Another study has demonstrated that anti-CTLA-4 treatment increases the action of Treg and CD4 T cells but decreases the action of CD8 T cells. Methods Eligible pts had ≥2 prior systemic treatments (1 platinum-based CT), WHO PS 0/1, no prior PDx and were EGFR/ALK WT. Design, setting, and participants: The CONDOR study was a phase 2, randomized, open-label study of Durvalumab, Tremelimumab, and Durvalumab in Combination With Tremelimumab in Patients With R/M HNSCC. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. The primary endpoint of the study was OS; secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety and tolerability. Future explorations are needed to further confirm the application of durvalumab plus tremelimumab. [40]. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Heterogeneity among the studies was tested by I2 statistic percentages and the Cochran Q Chi-squared test. Curr Opin Immunol 2012;24:207–12. While compared with tremelimumab monotherapy, combination therapy showed a higher risk of any grade treatment-related adverse events in HNSCC (RR 1.05) but a lower risk in GGA (RR 0.68). All data generated or analyzed during this study are included in this published article [and its supplementary information files].